Tab. V.
Clinicians’ perceptions.
| The clinicians’ perceptions | ||
|---|---|---|
| Ethical aspects | PREP | No PREP |
| Access to care on local level | 0.25 | 0.00 |
| Access to care for persons on a legally protected status | 0.69 | 0.00 |
| Impact of the preventive strategy on the accessibility to care related to the management of adverse events | -0.81 | 0.00 |
| Generation of health migration phenomena | 0.43 | 0.00 |
| Impact of the preventive strategy on the patients’ willingness to pay | -1.19 | 0.00 |
| General equity | -0.44 | 0.00 |
| Accessibility to the prevention strategy, in case of full payment by the potential PrEP users | -1.84 | 0.00 |
| Accessibility to the prevention strategy, in case of co-payment. | -1.09 | 0.00 |
| Average value | -0.50 | 0.00 |
| Social aspects | PREP | No PREP |
| Ability of the drug to protect the potential PrEP users’ autonomy | 0.00 | 0.00 |
| Ability of the drug to protect the human rights | 0.00 | 0.00 |
| Ability of the drug to protect the potential PrEP users’ integrity | 0.00 | 0.00 |
| Ability of the drug to protect the potential PrEP users’ dignity | 0.00 | 0.00 |
| Impact of the drug on potential PrEP users’ religion | 0.00 | 0.00 |
| Impact of the drug on social costs | -1.76 | 0.00 |
| Impact of the drug on the citizens’ medicalization | -0.91 | 0.00 |
| Impact of the drug on the potential PrEP users’ satisfaction | 1.52 | 0.00 |
| Impact of the drug on the potential PrEP users’ perceived quality of life | 0.98 | 0.00 |
| Impact of the drug on the potential PrEP users’ lifestyle | 0.19 | 0.00 |
| Impact of the drug on sexual behaviors disinhibition | -2.21 | 0.00 |
| Average value | -0.20 | 0.00 |
| Legal aspects | PREP | No PREP |
| Authorization level (national/European/international) | -1.94 | 0.00 |
| Legal impact on safety issues | -1.18 | 0.00 |
| Infringement of intellectual property rights | -0.48 | 0.00 |
| Impact on the production warranties | -0.79 | 0.00 |
| Need to regulate the drug acquisition and costs | -1.48 | 0.00 |
| The legislation covers the regulation of technology for all categories of patients | -1.00 | 0.00 |
| Impact on the not-availability of PrEP in hospitals | -1.58 | 0.00 |
| Average value | -1.21 | 0.00 |
| Organisational aspects | PREP | No PREP |
| Additional staff | -1.44 | 0.00 |
| Training courses devoted to Infectious Disease clinicians | -1.35 | 0.00 |
| Training courses devoted to healthcare professionals | -1.41 | 0.00 |
| Training course devoted to potentially PrEP users | -1.38 | 0.00 |
| Internal hospital meetings | -1.35 | 0.00 |
| Additional rooms | -1.00 | 0.00 |
| Additional furniture | -0.59 | 0.00 |
| Impact on the internal processes | -1.26 | 0.00 |
| Impact on the processes between the Pharmaceutical Department and the Infectious Diseases Department | -0.76 | 0.00 |
| Impact of the number of access for conducting HIV tests | -0.68 | 0.00 |
| Impact on the number of hematological exams, specialist visits related to the administration of the drug | -1.68 | 0.00 |
| Impact on the management of other infectious diseases, different from HIV and HBV | -2.06 | 0.00 |
| Organisational impact on the development of complications and adverse events | -0.47 | 0.00 |
| Organisational impact on the development of drug toxicities and resistance | -1.21 | 0.00 |
| Impact on the taking in charge of a higher number of individuals | -1.62 | 0.00 |
| Average value | -1.22 | 0.00 |